Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 160 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Irritation; Vagina Clear all
Completed Phase 3 Interventional

Treatment of Bacterial Vaginosis With Oral Tinidazole

NCT00229216
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Tinidazole
Drug
Lead sponsor
Mission Pharmacal
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 25, 2026, 9:11 AM EDT
Recruiting Phase 2 Interventional

Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women

NCT06197568
View directory record Official record
Conditions
Vulvo Vaginal Atrophy (VVA)
Interventions
Lasofoxifene Tartrate
Drug
Lead sponsor
Azure Biotech Inc.
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 25, 2026, 9:11 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome

NCT05753813
View directory record Official record
Conditions
Bacterial Vaginosis, Vulvovaginal Candidiasis
Interventions
Phexxi
Drug
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

NCT02013544
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, Prasterone (DHEA)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TOL-463 Phase 2 Study for Vaginitis

NCT02866227
View directory record Official record
Conditions
Bacterial Vaginosis, Vulvovaginal Candidiasis
Interventions
TOL-463
Drug
Lead sponsor
Toltec Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 25, 2026, 9:11 AM EDT
Terminated Early Phase 1 Interventional

LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study

NCT02197182
View directory record Official record
Conditions
Bacterial Vaginosis (BV)
Interventions
LUXSOL copper containing cream, Metronidazole gel
Drug
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

NCT03937869
View directory record Official record
Conditions
Bacterial Vaginoses
Interventions
Secnidazole
Drug
Lead sponsor
Lupin Research Inc
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
Long Beach, California • Hialeah, Florida • Miami Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections

NCT03840616
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule, Placebo
Drug
Lead sponsor
Mycovia Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Tucson, Arizona • Encino, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

DHEA Against Vaginal Atrophy - 3-Month Efficacy Study

NCT01256684
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 3 Interventional

Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis

NCT00137371
View directory record Official record
Conditions
Atrophic Vaginitis, Atrophy, Vaginitis
Interventions
PVC (daily for 21 days, 7 days off), PVC (twice weekly)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
480 participants
Timeline
2005 – 2007
U.S. locations
32
States / cities
Tucson, Arizona • Encinitas, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2007 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463

NCT01812889
View directory record Official record
Conditions
Vaginal Infection
Interventions
TOL-463 Vaginal ovule, TOL-463 Vaginal gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis

NCT02418845
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
SYM-1219, Placebo
Drug
Lead sponsor
Symbiomix Therapeutics
Industry
Eligibility
12 Years and older · Female only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
21
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 25, 2026, 9:11 AM EDT
Recruiting Not applicable Interventional

Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant Lesions

NCT06070454
View directory record Official record
Conditions
Vaginitis, Vulvar Diseases
Interventions
Vaginitis panel
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 25, 2026, 9:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women

NCT02272231
View directory record Official record
Conditions
Vaginosis, Bacterial
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

NCT05399641
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • San Diego, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219

NCT02452866
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
SYM-1219
Drug
Lead sponsor
Symbiomix Therapeutics
Industry
Eligibility
12 Years and older · Female only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Bacterial Vaginosis (BV) With Tinidazole

NCT00334633
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
tinidazole, metronidazole
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 2 Interventional

MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

NCT01497223
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
MGCD290
Drug
Lead sponsor
MethylGene Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • Lake Worth, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 25, 2026, 9:11 AM EDT
Terminated Phase 1 Interventional

Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity

NCT03954990
View directory record Official record
Conditions
Bacterial Vaginoses
Interventions
Metronidazole Oral, Placebo Oral Tablet
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Not applicable Interventional

Randomized, Double-Blind Placebo-Controlled Trial to Assess Overall User Experience of a Synbiotic Vaginal Suppository

NCT06236893
View directory record Official record
Conditions
Vaginal Personal Care
Interventions
VH-01 vaginal suppository tablet, Placebo vaginal suppository tablet
Other
Lead sponsor
Seed Health
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 25, 2026, 9:11 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prospective Data Bank Creation to Study Vaginal Conditions

NCT01829204
View directory record Official record
Conditions
Vulvodynia, Mycoses, Bacterial Vaginosis, Preterm Labor
Interventions
Not listed
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Midland, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Not applicable Interventional Results available

Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial

NCT00545181
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Vaginal acidifying gel (RepHresh), Metronidazole control
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin D and Sexual Health

NCT01450462
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Vitamin D3 (cholecalciferol), Placebo
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Topical DHEA Against Vaginal Atrophy

NCT01846442
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA (0.25%), DHEA (0.5%), DHEA (1.0%)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Cleveland, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 25, 2026, 9:11 AM EDT